Shares of Annovis Bio, Inc. (ANVS) have gained 0.1% over the past four weeks to close the last trading session at $7.29, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $33.50 indicates a potential upside of 359.5%.The average comprises four short-term price targets ranging from a low of $13 to a high of $72, with a standard deviation of $26.26. While the lowest estimate indicat ...

Core Insights - Annovis Bio, Inc. has published a new article in the journal Biomolecules, focusing on the pharmacokinetic profiles of Posiphen across different species, which consolidates years of research and provides a comprehensive comparison of the drug's behavior in various animal and human samples [1][2]. Group 1: Research Findings - The article presents findings that Posiphen quickly reaches peak concentration in plasma, followed by high absorption in the brain and cerebrospinal fluid (CSF) [2]. - Posiphen metabolizes into two primary metabolites: N1-norposiphen and N8-norposiphen, with both the drug and its metabolites exhibiting rapid clearance in animal models and human subjects, although the drug remains longer in the CSF or brain [2]. - The absorption, distribution, metabolism, and excretion of Posiphen are similar in healthy volunteers and patients with Alzheimer's and Parkinson's diseases [2]. Group 2: Company Overview - Annovis Bio, Inc. is a clinical-stage drug platform company headquartered in Malvern, Pennsylvania, focusing on neurodegenerative diseases such as Alzheimer's Disease (AD) and Parkinson's Disease (PD) [3]. - The company is believed to be the only one developing a drug targeting multiple neurotoxic proteins to restore axonal and synaptic activity, aiming to improve brain function and address memory loss and dementia associated with AD, as well as body and brain dysfunction related to PD [3].

MALVERN, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the publication of a new article focused on the comparison of pharmacokinetic profiles of Posiphen (or buntanetap) across different species in a peer-reviewed journal Biomolecules as part of the Special Issue: Role of Amyloid Protein in Neurological Diseases. “This publication is a testament to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2024 ANNOVIS BIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) | --- | --- | --- | |-------|-------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 001-39202 | | | | | | | | | | | | (Commission | ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-39202 Annovis Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2540421 (State or other jurisdiction of incorporation or organiz ...

MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson's disease (PD). Topline efficacy data is expected in June. The Phase III study was completed in 4Q 2023 with an original plan for data announcement in 1Q 2024, however the Company f ...

Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild ADImprovement in cognition measured by ADAS-Cog 11 at three months is 3.3 points as compared to 0.3 for placebo, consistent with our previous Phase II AD/PD and Discover studies Plasma Tau protein levels are reduced, consistent with our previous Phase II biomarker dataBased on the findings of this symptomatic study, Annovis plans to conduct a pivotal disease-modifying Phase III tr ...

Shares of Annovis Bio, Inc. (ANVS) have gained 0.9% over the past four weeks to close the last trading session at $11.88, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $35.40 indicates a potential upside of 198%.The mean estimate comprises five short-term price targets with a standard deviation of $22.13. While the lowest estimate of $13 indicates a 9.4% increase from the curr ...

Shares of Annovis Bio, Inc. (ANVS) have gained 23.8% over the past four weeks to close the last trading session at $11.10, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $35.40 indicates a potential upside of 218.9%.The average comprises five short-term price targets ranging from a low of $13 to a high of $72, with a standard deviation of $22.13. While the lowest estimate indic ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39202 Annovis Bio, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpora ...